Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
about
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistanceMolecular profiles of BRCA1-mutated and matched sporadic breast tumours: relation with clinico-pathological featuresElevated expression of polymorphonuclear leukocyte elastase in breast cancer tissue is associated with tamoxifen failure in patients with advanced disease.Hormone receptor and ERBB2 status in gene expression profiles of human breast tumor samplesRelevance of BCAR4 in tamoxifen resistance and tumour aggressiveness of human breast cancer.Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer.Somatostatin receptors in differentiated ovarian tumorsBreast cancer prognosis is poor when total plasminogen activator activity is lowResponse to adjuvant chemotherapy in primary breast cancer: no correlation with expression of glutathione S-transferases.Differential biological significance of tissue-type and urokinase-type plasminogen activator in human breast cancerHigh miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer.Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.The 29.5 kb APOBEC3B Deletion Polymorphism Is Not Associated with Clinical Outcome of Breast Cancer.Breast carcinomas occurring in young women (< 35 years) are different.The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancerDetermination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival.Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients.Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancerPrognostic value of tissue-type plasminogen activator (tPA) and its complex with the type-1 inhibitor (PAI-1) in breast cancer.Prognostic impact of urokinase-type plasminogen activator receptor (uPAR) in cytosols and pellet extracts derived from primary breast tumours.CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting.Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
P2860
Q24642804-5AF5356E-6A0E-4A75-BE4A-48B2DC1AFE9DQ33182341-8EA2AA6C-311F-4898-994E-ADA4C2755EBCQ33186595-2D51F5CE-FD3A-4DAE-B603-DB2BE63F6420Q34055901-6D23D55E-B20E-4543-963E-CD2E93E6D475Q34255976-4DECA99B-0905-4060-9A7C-0F816FB0A573Q34613612-A851CD38-BDAA-4DBA-908A-D57571A69F0CQ34816422-4F0E8211-7B18-4C22-B3E3-2F361521C37CQ35830314-63C72C8C-F78A-42F1-BAB6-AA775C1B5F95Q35975691-F972C58E-F1FC-4287-8B15-7013D0FB25AAQ35976146-B7FD8C22-7487-435F-9A14-BBFAB3E10780Q35976553-8EE23B8B-ED60-4869-8DEE-D4EEBF340A79Q36070061-975CD948-0F1E-4638-878E-35C9A876597DQ36080684-B62A9AC4-75E2-4AE9-BDEA-134EABA511E9Q36110285-B48245C0-6C36-4B84-817B-95AF15F4CA02Q36141250-3375A285-3729-43BD-9704-5FEECFD555C7Q36430961-24DFB45B-90F9-45A9-B4C2-BDE6F868EADDQ36613581-E188364D-24E4-4D34-A6C6-D906D20B5BE4Q36617364-851E4BE1-1D77-420F-A89B-C8704F8FE0D0Q36617616-107B5EC0-82B7-4E6F-AAE4-2CC8CE09C66CQ36618953-0F79D27A-62F4-4BAF-9C48-6A9B1404E5EEQ36620072-EFCB740B-5284-4E65-96C9-1DBAEEE6BEEEQ36623099-5A6451D8-EFC9-4857-A183-A5EF0E3B88E0Q37457732-01DB061E-75C9-432B-8F07-12444999248DQ37467255-0181BED1-DD89-4944-A854-C0DBD98BC6E1Q41135362-ABF2D3F8-833A-4E2B-B091-EECA830571A5Q42573382-BEF4F1C4-3BB7-4822-B97D-009B1F7F8E97
P2860
Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@ast
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@en
type
label
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@ast
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@en
prefLabel
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@ast
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@en
P2093
P1433
P1476
Prognostic value of estrogen a ...... n human breast tumor cytosols.
@en
P2093
Alexieva-Figusch J
Foekens JA
Krijnen HL
Portengen H
van Putten WL
P304
P407
P577
1989-11-01T00:00:00Z